Y
Exchange
—
Entity type
operating
Fiscal year end
Dec 31
Headquarters
DE
Recent Filings
- 8-K317.0 KBY-mAbs Therapeutics, Inc.Sep 16, 8:59 AM ET·0001104659-25-090232
- 10-Q11.3 MBY-mAbs Therapeutics, Inc.Aug 8, 7:30 AM ET·0001558370-25-010848
- 8-K656.0 KBY-mAbs Therapeutics, Inc.Aug 8, 7:18 AM ET·0001558370-25-010846
- 8-K1.1 MBY-mAbs Therapeutics, Inc.Aug 5, 9:30 AM ET·0001104659-25-073993
- 8-K201.0 KBY-mAbs Therapeutics, Inc.Jul 15, 4:15 PM ET·0001104659-25-068099
- 8-K10.0 MBY-mAbs Therapeutics, Inc.May 28, 7:04 AM ET·0001104659-25-053289
- 10-Q9.1 MBY-mAbs Therapeutics, Inc.May 13, 7:33 AM ET·0001558370-25-007492
- 8-K522.3 KBY-mAbs Therapeutics, Inc.May 13, 7:26 AM ET·0001558370-25-007491
- 10-K/A1.3 MBY-mAbs Therapeutics, Inc.Apr 28, 8:14 PM ET·0001104659-25-040396
- 8-K596.4 KBY-mAbs Therapeutics, Inc.Mar 4, 4:26 PM ET·0001558370-25-002174
Insiders
10- Ahmed MahiuddinSr. VP & Chief Scientific Off
- Ber GerardDirector
- Buschle MichaelDirector
- Gad ThomasDirector, CHIEF BUSINESS OFFICER
- Gentilcore Douglas JSVP, Danyelza Bus. Unit Head
- GILL DAVID NDirector
- Hamill LauraDirector
- HEALY JAMESDirector
- Herman Philip KarlSr. VP and CCO
- Kruse BoDirector, EVP, CFO, Secy & Treas.
Tickers
No tickers on record
Addresses
business
202 CARNEGIE CENTER SUITE 301
PRINCETON, NJ, 08540
mailing
202 CARNEGIE CENTER SUITE 301
PRINCETON, NJ, 08540